RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Heart failure patients have new hope

Feb 13, 2012 - 5:00:00 AM

Studies have shown that heart failure patients treated with American Heart Association/American College of Cardiology guideline-recommended therapies are more likely to survive over the next two years. Every 10 percent improvement in the use of guideline-recommended therapies has been associated with a 13 percent lower risk of death among heart failure patients over the next two years. (Fonarow G, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation. 2011;123:1601-1610)


 
[RxPG] Despite the increasing number of people affected, the prognosis for patients with heart failure has steadily improved, said Gregg C. Fonarow, M.D, chairman of American Heart Association Hospital Accreditation Science Committee and professor of cardiovascular medicine of the University of California, Los Angeles. This is testament in part to better therapies and systems for treating this condition. There has been so much research and advancement in this area that what used to be a very dismal diagnosis is no longer the norm. Used appropriately, available medical and device therapies are even more effective than originally believed and best practices of care have now been shown to save lives.

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through the heart to meet the body's needs for blood and oxygen. Basically, the heart can't keep up with its workload.

The weakened heart can't supply the cells with enough blood. This results in fatigue and shortness of breath. Everyday activities such as walking, climbing stairs or carrying groceries can become difficult.

Heart failure is caused by damage to the heart that impairs its ability to function. However, even for the patient with chronic heart muscle weakness, a significant amount of heart function can now be restored by the correct use of heart failure medication and devices.

Even for our patients with advanced disease, there are so many more options now available to us, said Clyde Yancy, M.D., past president of the American Heart Association and chief of the Division of Cardiology and the Magerstadt Professor at Northwestern University Feinberg School of Medicine in Chicago. The use of mechanical support such as artificial heart pumping devices, has become remarkable. We can sustain patients long enough to not only allow for heart transplantation but also to serve as definitive therapy and even more provocatively to support recovery of heart muscle function even when seemingly dramatic changes have taken place.

Along with advanced technologies, improvements in quality of care are also making a difference in heart failure outcomes.

Studies have shown that heart failure patients treated with American Heart Association/American College of Cardiology guideline-recommended therapies are more likely to survive over the next two years. Every 10 percent improvement in the use of guideline-recommended therapies has been associated with a 13 percent lower risk of death among heart failure patients over the next two years. (Fonarow G, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation. 2011;123:1601-1610)





Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)